Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
The primary purpose of this study is to characterize the safety and tolerability of tucatinib (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma (GEC), and colorectal cancer.
Metastatic HER2+ Advanced Breast Cancer|Breast Neoplasms|Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)|Colorectal Cancer
DRUG: Tucatinib
Percentage of participants with ≥1 adverse event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 2.5 years|Percentage of participants discontinuing from study therapy due to AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 2.5 years
Maximum plasma concentration (Cmax) of first dose of tucatinib, The Cmax of tucatinib will be determined after the first dose., Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Time of maximum plasma concentration (Tmax) of first dose of tucatinib, The Tmax of tucatinib will be determined after the first dose., Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Area under the plasma concentration time curve from dosing to 12 hours postdose (AUC0-12) of first dose of tucatinib, The AUC0-12 of tucatinib will be determined after the first dose., Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Apparent plasma half-life (t½) of first dose of tucatinib, The t½ of tucatinib will be determined after the first dose., Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Apparent clearance (CL/F) of first dose of tucatinib, The CL/F of tucatinib will be determined after the first dose., Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Volume of distribution (Vz/F) of first dose of tucatinib, The Vz/F of tucatinib will be determined after the first dose., Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Trough concentration (Ctrough) of tucatinib at steady state, The Ctrough of tucatinib will be determined at steady state., Cycle 1, Days 8 and 15: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Accumulation ratio of tucatinib at steady state, The accumulation ratio of tucatinib will be determined at steady state., Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Cmax at steady state (Cmaxss) of tucatinib, The Cmaxss of tucatinib will be determined at steady state., Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Tmax at steady state (Tmaxss) of tucatinib, The Tmaxss of tucatinib will be determined at steady state., Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|AUC0-12 at steady state (AUC0-12ss) of tucatinib, The AUC0-12ss of tucatinib will be determined at steady state., Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|t½ of tucatinib at steady state, The t½ of tucatinib will be determined at steady state., Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|CL/F at steady state (CL/Fss) of tucatinib, The CL/Fss of tucatinib will be determined at steady state., Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Vz/F at steady state (Vz/Fss) of tucatinib, The Vz/Fss of tucatinib will be determined at steady state., Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose|Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), ORR is defined as the percentage of participants who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR based on RECIST 1.1 will be presented., Up to approximately 19 months|Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death., Up to approximately 19 months
The primary purpose of this study is to characterize the safety and tolerability of tucatinib (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma (GEC), and colorectal cancer.